Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3909197 | 1.00 | ALDH1A1 (0.51) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL45484 | 0.84 | LMNA (0.38) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL515504 | 0.84 | LMNA (0.38) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL45483 | 0.84 | LMNA (0.38) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL7237829 | 0.81 | DRD2 (0.39) | ALDH1A1LMNAKMT2AMAPTKDM4E | |
| SCHEMBL13168806 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL18623488 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2ARECQLGAA | |
| SCHEMBL16093059 | 0.78 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2ARECQLGAA | |
| Thiamethoxam SCHEMBL3956094 | 0.77 | LMNA (0.38) | ALDH1A1LMNAKMT2ARECQLGAA | |
| Thiamethoxam SCHEMBL22916 | 0.77 | LMNA (0.38) | ALDH1A1LMNAKMT2ARECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009149676-A | METHOD FOR PRODUCING 1,3-DISUBSTITUTED 2-NITROGUANIDINES | BAYER CROPSCIENCE AG | 2009-07-09 | — | — | JP | disclosed |
| US-7026307-B2 | Method for producing 1,3-disubstituted 2-nitroguanidines | BAYER CROPSCIENCE AG (DE) | 2006-04-11 | — | — | US | disclosed |
| EP-1392652-B1 | METHOD FOR PRODUCING 1,3-DISUBSTITUTED 2-NITROGUANIDINES | BAYER CROPSCIENCE AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20040167177-A1 | Method for producing 1,3-disubstituted 2-nitroguanidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-08-26 | — | — | US | disclosed |
| EP-1242390-B1 | METHOD FOR PRODUCTION OF 1,3-DISUBSTITUTED 2-NITROGUANIDINES | BAYER CROPSCIENCE AG (DE) | 2004-08-11 | — | — | EP | disclosed |
| EP-1066251-B1 | METHOD FOR THE PRODUCTION OF 1,3-DISUBSTITUTED 2-NITROGUANIDINES | BAYER CROPSCIENCE AG (DE) | 2003-07-09 | — | — | EP | disclosed |
| US-6528651-B1 | Ring cleavage deamination of a triazacylclohexane derivative with hydrogen chloride | BAYER AKTIENGESELLSCHAFT (DE) | 2003-03-04 | — | — | US | disclosed |
| EP-1242390-A1 | METHOD FOR PRODUCTION OF 1,3-DISUBSTITUTED 2-NITROGUANIDINES | Bayer Aktiengesellschaft (DE) | 2002-09-25 | — | — | EP | disclosed |
| EP-0971907-B1 | METHOD FOR PRODUCING 1,3-DI-SUBSTITUTED 2-NITROGUANIDINES | BAYER AG (DE) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001046160-A1 | METHOD FOR PRODUCTION OF 1,3-DISUBSTITUTED 2-NITROGUANIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-28 | — | — | WO | disclosed |
| US-6194575-B1 | REACTING 2-NITROIMINO-3,5-DIMETHYL-1,3, 5-TRIAZA-CYCLOHEXANE DERIVATIVE WITH UREA IN PRESENCE OF DILUENT TO FORM 1,3-DI-SUBSTITUTED 2-NITROGUANIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-02-27 | — | — | US | disclosed |
| EP-1066251-A1 | METHOD FOR THE PRODUCTION OF 1,3-DISUBSTITUTED 2-NITROGUANIDINES | Bayer Aktiengesellschaft (DE) | 2001-01-10 | — | — | EP | disclosed |
| EP-0971907-A1 | METHOD FOR PRODUCING 1,3-DI-SUBSTITUTED 2-NITROGUANIDINES | Bayer Aktiengesellschaft (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999042437-A1 | METHOD FOR THE PRODUCTION OF 1,3-DISUBSTITUTED 2-NITROGUANIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-26 | — | — | WO | disclosed |
| WO-1998042690-A1 | METHOD FOR PRODUCING 1,3-DI-SUBSTITUTED 2-NITROGUANIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167177-A1 | Method for producing 1,3-disubstituted 2-nitroguanidines | PTGS2, PTGS1, HPGD | ALDH1A1 198/4885LMNA 3709/4885KMT2A 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.